1  BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The applicant Novartis Europharm Limited submitted on 28 April 2005 an application for Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for 
Exjade, which was designated as an orphan medicinal product EU/3/02/092 on 13 March 2002. Exjade 
was designated as an orphan medicinal product in the following indication:  treatment of chronic iron 
overload requiring chelation therapy. The calculated prevalence of this condition was 102,000 persons 
in the EU. 
The  legal  basis  for  this  application  refers  to  Article  8.3  of  Directive  2001/83/EC,  as  amended  - 
complete and independent application. 
The  applicant  applied  for  the  following  indication:  treatment  of  chronic  iron  overload  due  to  blood 
transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over). 
Protocol Assistance: 
The applicant received Protocol Assistance from the CHMP on 25 July 2002 and 17 December 2003. 
The Protocol Assistance pertained to non-clinical and clinical aspects of the dossier.  
Licensing status: 
A new application was filed in the following countries: USA 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Eric Abadie  
Co-Rapporteur: Giuseppe Nistico 
1.2  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 28 April 2005.  
The procedure started on 18 May 2005. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 28 July 2005 
The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
28 July 2005.  
During  the  meeting  on  12-15  September  2005,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 15 September 2005.  
A clarification meeting on the List of Questions was held on 16 November 2005. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
11 January 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  27 February 2006.  
During  the  CHMP  meeting  on  20-23  March  2006  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and in an oral explanation by the applicant.  
The applicant submitted the responses to the CHMP list of outstanding issues on 3 May 2006. 
The Rapporteurs circulated the updated Joint Assessment Report on the applicant’s responses to 
the list of outstanding issues to all CHMP members on 19 May 2006. 
During  the  CHMP  meeting  on  29  May-1  June  the  outstanding  issues  were  addressed  by  the 
applicant during an oral explanation before the CHMP. 
During  the  CHMP  meeting  on  29  May-1  June  2006  the  CHMP  agreed  on  a  second  list  of 
outstanding issues to be addressed in writing by the applicant. 
The applicant submitted the responses to the CHMP second list of outstanding issues following 
an oral explanation on 6 June 2006. 
The Rapporteurs circulated the revised Joint Assessment Report on the applicant’s responses to 
the second list of outstanding issues to all CHMP members on 26 June 2006.  
©EMEA 2006                
                                                     1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
During the meeting on  26-28 June 2006, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Exjade  on  28  June  2006.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 28 June 2006. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 28 August 2006. 
©EMEA 2006           
                                                     2/2 
 
 
 
 
 
